Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new? by Alexander Chehrazi-Raffle, Sumanta Kumar Pal

Get full text

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors by Sumanta Kumar Pal, Robert A. Figlin

Get full text

Critical appraisal of cabazitaxel in the management of advanced prostate cancer by Sumanta Kumar Pal, Przemyslaw Twardowski, Oliver Sartor

Get full text

The Gut Microbiome and Metastatic Renal Cell Carcinoma by Luis Meza, Matthew Feng, Kyle Lee, Rubens Sperandio, Sumanta Kumar Pal

Get full text

Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices by Nicholas J. Salgia, Errol J. Philip, Mohammadbagher Ziari, Kelly Yap, Sumanta Kumar Pal

Get full text

Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches by Tanya Barauskas Dorff, Saro Kasparian, Natasha Garg, Sandy Liu, Sumanta Kumar Pal, Jeffrey Wong, Savita Dandapani

Get full text

Conditional Survival in de novo Metastatic Urothelial Carcinoma. by Sumanta Kumar Pal, Yulan Ingrid Lin, Bertram Yuh, Kara DeWalt, Austin Kazarian, Nicholas Vogelzang, Rebecca A Nelson

Get full text

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database by Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, Elizabeth R. Plimack, Lauren C. Harshman, Evan Y. Yu, Simon J. Crabb, Sumanta Kumar Pal, Ajjai S. Alva, Thomas Powles, Ugo De Giorgi, Neeraj Agarwal, Aristotelis Bamias, Sylvain Ladoire, Andrea Necchi, Ulka N. Vaishampayan, Günter Niegisch, Joaquim Bellmunt, Jack Baniel, Matthew D. Galsky, Cora N. Sternberg

Get full text